NCT06311721 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06311721
Title	A Study to Compare ABP 234 and Keytruda (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Amgen
Indications	lung non-squamous non-small cell carcinoma
Therapies	Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab ABP 234 + Cisplatin + Pemetrexed Disodium ABP 234 + Carboplatin + Pemetrexed Disodium ABP 234 + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BGR \| AUT \| ARG

Additional content available in CKB BOOST